1. Wang X, Zhao C, Gong Y, Wang Y, Guo F. Multidrug resistance in the standardized treatment of colon cancer harboring a rare fibrosarcoma B-type (BRAF) p.N581I mutation: a case report. Front Oncol. 2023 Jul ...
Right-sided colon cancerImaging characteristicsBackground Colorectal cancer (CRC) is one of the leading causes of cancer deaths and is associated with various genetic mutations. BRAF mutations, found in approximately 10% of all CRCs, are associated with negative predictive outcomes. The goal of this...
BRAF mutation as a potential therapeutic target for checkpoint inhibitors: a comprehensive analysis of immune microenvironment in BRAF mutated colon cancer. Front. Cell Dev. Biol. 9, 705060 (2021). PubMed PubMed Central Google Scholar Clarke, C. N. & Kopetz, E. S. BRAF mutant colorectal ...
参考文献: Kono H, Yamanaka T, Nishihara Y, Tomizawa K, Kizawa R, Yamaguchi T, Tanabe Y, Matoba S, Kuroyanagi H, Suyama K, Miura Y. BRAF Mutation Heterogeneity Detected Using Circulating Tumor DNA Sequencing in Synchronous Colon Cancer: A Case Report. Cancer Diagn Progn. 2023 Sep 3;3(5...
BRAF Mutation Heterogeneity Detected Using Circulating Tumor DNA Sequencing in Synchronous Colon Cancer: A Case Report. Cancer Diagn Progn. 2023 Sep 3;3(5):605-608. doi: 10.21873/cdp.10262. PMID: 37671312; PMCID: PMC10475923.发布于 2023-09-26 10:16・IP 属地江苏...
553O - Prognostic value of KRAS and BRAF mutations in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: An ACCENT/IDEA pooled analysis of 7 trials Background Whether KRAS and BRAFV600E mutations ...
The NCCN Colon/Rectal Cancer Panel believes that RAS mutation status should be determined at diagnosis of stage IV disease. Patients with any known RAS mutation should not be treated with either cetuximab or panitumumab....
Kono H, Yamanaka T, Nishihara Y, Tomizawa K, Kizawa R, Yamaguchi T, Tanabe Y, Matoba S, Kuroyanagi H, Suyama K, Miura Y. BRAF Mutation Heterogeneity Detected Using Circulating Tumor DNA Sequencing in Synchronous Colon Cancer: A Case Report. Cancer Diagn Progn. 2023 Sep 3;3(5):605-608...
The BRAF V600E mutation is an independent prognostic factor for survival in stage Ⅱ and stage Ⅲ coloncancer patients[J]. Ann Oncol, 2010, 21(12):2396-2402. [14] Ogino S, Shima K, Meyerhardt J A, et al. Predictive and prognostic roles of BRAF mutation in stage Ⅲ colon cancer: ...
参考文献:Wang X, Zhao C, Gong Y, Wang Y and Guo F (2023) Multidrug resistance in the standardized treatment of colon cancer harboring a rare fibrosarcoma B-type (BRAF) p.N581I mutation: a case report. Front. Oncol. 13:1175693. doi: 10.3389/fonc.2023.1175693...